Regulatory
FDA Approves Lilly’s Onswik, a Once-Weekly Insulin for Type 2 Diabetes
Efsitora alfa turns 365 basal insulin injections a year into 52. It is the second weekly insulin cleared in the US this year — and a sign that diabetes care is shifting toward fewer, longer-acting doses.